Yunkang Group 2022 In the first half of the year, the net profit of 234 million yuan, an increase of 49.97% year -on -year

On August 11, 2022, Yunkang Group (code: 02325.HK), a listed company of Hong Kong stocks, released the 2022 fiscal year.

From January 1, 2022-June 30, 2022, the company's operating income was 1.379 billion yuan, an increase of 81.87%year-on-year, and the net profit attributable to the parent company was 234 million yuan, an increase of 49.97%year-on-year, and the basic earnings per share were 0.44 yuan.

The company's industry serves health care.

Among them, the diagnostic testing income was 1.379 billion yuan.

During the company's reporting period, the total assets at the end of the period were 3.892 billion yuan, and the profit before tax was 284 million yuan.

Yunkang Group Co., Ltd. is a medical operation service provider in China. It provides a full set of diagnostic testing services for Chinese medical institutions. Based on revenue, the company's market share in the Chinese medical operation service market in 2020 is 3.7%. Medical operation services are mainly related to diagnostic testing services provided to medical institutions. These services can be divided into diagnostic outsourcing services and diagnostic testing services provided by the medical federation. The company provides such diagnostic testing services to medical institutions in six independent clinical laboratories (‘ICL’) and on -site diagnostic centers, and collects diagnostic service fees from the type and quantity of the testing. According to Fhstanalin, the Chinese medical operation service market is expected to increase from RMB 30.695 billion in 2020 to RMB 47.946 billion in 2025, with a compound annual growth rate of 9.3%.

- END -